Primary central nervous system effusion plasmablastic lymphoma in immunocompromised patient: A rare phenomenon

Brij Mohan Singh, Sushma Belurkar, Arijit Bishnu, Tanvi Shetty, P. Pavithra

Research output: Contribution to journalArticle

Abstract

Primary effusion lymphoma (PEL) is an aggressive neoplasm with a high rate of fatality. PEL cells are known to have morphological diversities, which range from immunoblastic or plasmablastic to anaplastic. Most of these cases are described in immunocompromised as well as immunocompetent patients. Plasmablastic lymphoma remains a diagnostic challenge, especially when encountered with the presentation as PEL. In spite of therapeutic advances, PEL remains an aggressive disease with a high rate of fatality. We describe one case of this extremely rare neoplasm in an immunocompromised patient presenting in the form of primary central nervous system effusion plasmablastic lymphoma. To the best of our knowledge, this is the first case ever been reported in the literature.

Original languageEnglish
Pages (from-to)6-7
Number of pages2
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume11
Issue number8
DOIs
Publication statusPublished - 01-01-2018

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Primary central nervous system effusion plasmablastic lymphoma in immunocompromised patient: A rare phenomenon'. Together they form a unique fingerprint.

  • Cite this